Listed

Elicio Therapeutics, Inc.

ELTXNasdaqCIK 1601485HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$10.4m, Q2 FY2026
Net income−$8.2m, Q2 FY2026
Elicio Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m7.3Research and development, Q3 FY2023, three months to 2023-09-30$7.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure6.2Research and development, Q4 FY2023, three months to 2023-12-31$6.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-31, accession 0001601485-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure7.6Research and development, Q1 FY2024, three months to 2024-03-31$7.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure8.2Research and development, Q2 FY2024, three months to 2024-06-30$8.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure7.2Research and development, Q3 FY2024, three months to 2024-09-30$7.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure10.7Research and development, Q4 FY2024, three months to 2024-12-31$10.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure7.8Research and development, Q1 FY2025, three months to 2025-03-31$7.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure7.0Research and development, Q2 FY2025, three months to 2025-06-30$7.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure5.0Research and development, Q3 FY2025, three months to 2025-09-30$5.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure5.1Research and development, Q4 FY2025, three months to 2025-12-31$5.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure6.8Research and development, Q1 FY2026, three months to 2026-03-31$6.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure6.8Research and development, Q2 FY2026, three months to 2026-06-30$6.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Operating income$m(10.8)Operating income, Q3 FY2023, three months to 2023-09-30−$10.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure(9.4)Operating income, Q4 FY2023, three months to 2023-12-31−$9.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001601485-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure(10.2)Operating income, Q1 FY2024, three months to 2024-03-31−$10.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure(10.9)Operating income, Q2 FY2024, three months to 2024-06-30−$10.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure(10.3)Operating income, Q3 FY2024, three months to 2024-09-30−$10.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure(13.5)Operating income, Q4 FY2024, three months to 2024-12-31−$13.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure(10.7)Operating income, Q1 FY2025, three months to 2025-03-31−$10.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure(10.1)Operating income, Q2 FY2025, three months to 2025-06-30−$10.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure(8.0)Operating income, Q3 FY2025, three months to 2025-09-30−$8.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure(8.8)Operating income, Q4 FY2025, three months to 2025-12-31−$8.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure(10.6)Operating income, Q1 FY2026, three months to 2026-03-31−$10.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure(10.4)Operating income, Q2 FY2026, three months to 2026-06-30−$10.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Interest expense$m0.0Interest expense, Q3 FY2023, three months to 2023-09-30$1.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-13, accession 0001601485-23-000082.Report this figure0.0Interest expense, Q4 FY2023, three months to 2023-12-31$2.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-03-29, accession 0001601485-24-000023. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2024, three months to 2024-03-31$36.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-15, accession 0001601485-24-000033.Report this figure0.0Interest expense, Q2 FY2024, three months to 2024-06-30$49.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure0.1Interest expense, Q3 FY2024, three months to 2024-09-30$137.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure0.2Interest expense, Q4 FY2024, three months to 2024-12-31$234.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure0.2Interest expense, Q1 FY2025, three months to 2025-03-31$176.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure0.2Interest expense, Q2 FY2025, three months to 2025-06-30$194.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure0.4Interest expense, Q3 FY2025, three months to 2025-09-30$426.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure0.3Interest expense, Q4 FY2025, three months to 2025-12-31$337.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure0.4Interest expense, Q1 FY2026, three months to 2026-03-31$407.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure0.4Interest expense, Q2 FY2026, three months to 2026-06-30$410.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-31, accession 0001601485-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Net income$m(10.7)Net income, Q3 FY2023, three months to 2023-09-30−$10.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure(8.9)Net income, Q4 FY2023, three months to 2023-12-31−$8.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001601485-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure(11.8)Net income, Q1 FY2024, three months to 2024-03-31−$11.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure(7.2)Net income, Q2 FY2024, three months to 2024-06-30−$7.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure(18.8)Net income, Q3 FY2024, three months to 2024-09-30−$18.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure(14.0)Net income, Q4 FY2024, three months to 2024-12-31−$14.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure(11.2)Net income, Q1 FY2025, three months to 2025-03-31−$11.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure(10.6)Net income, Q2 FY2025, three months to 2025-06-30−$10.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure(10.1)Net income, Q3 FY2025, three months to 2025-09-30−$10.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure(7.7)Net income, Q4 FY2025, three months to 2025-12-31−$7.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure(11.8)Net income, Q1 FY2026, three months to 2026-03-31−$11.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure(8.2)Net income, Q2 FY2026, three months to 2026-06-30−$8.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Diluted EPS$ per share(1.27)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figurenot reported(1.15)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure(0.64)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure(1.39)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figurenot reported(0.87)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure(0.66)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure(0.60)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figurenot reported(0.65)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure(0.43)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Basic EPS$ per share(1.27)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figurenot reported(1.15)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure(0.64)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure(1.39)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figurenot reported(0.87)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.87 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure(0.66)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure(0.60)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figurenot reported(0.65)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.65 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure(0.43)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.43 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure

Balance sheet

Cash and equivalents$23.5m, Q2 FY2026
Long-term debt$9.5m, Q2 FY2026
Shareholders' equity$7.9m, Q2 FY2026
Elicio Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m14.8Cash and equivalents, Q3 FY2023, at 2023-09-30$14.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure12.9Cash and equivalents, FY2023, at 2023-12-31$12.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-31, accession 0001601485-25-000049.Report this figure11.9Cash and equivalents, Q1 FY2024, at 2024-03-31$11.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure3.4Cash and equivalents, Q2 FY2024, at 2024-06-30$3.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure26.0Cash and equivalents, Q3 FY2024, at 2024-09-30$26.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure17.6Cash and equivalents, FY2024, at 2024-12-31$17.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-12, accession 0001601485-26-000027.Report this figure18.4Cash and equivalents, Q1 FY2025, at 2025-03-31$18.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure22.1Cash and equivalents, Q2 FY2025, at 2025-06-30$22.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure20.6Cash and equivalents, Q3 FY2025, at 2025-09-30$20.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure18.6Cash and equivalents, FY2025, at 2025-12-31$18.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure14.9Cash and equivalents, Q1 FY2026, at 2026-03-31$14.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure23.5Cash and equivalents, Q2 FY2026, at 2026-06-30$23.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Current assets$m19.9Current assets, Q3 FY2023, at 2023-09-30$19.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-13, accession 0001601485-23-000082.Report this figure16.3Current assets, FY2023, at 2023-12-31$16.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-31, accession 0001601485-25-000049.Report this figure14.1Current assets, Q1 FY2024, at 2024-03-31$14.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-15, accession 0001601485-24-000033.Report this figure6.7Current assets, Q2 FY2024, at 2024-06-30$6.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001601485-24-000045.Report this figure30.6Current assets, Q3 FY2024, at 2024-09-30$30.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure20.7Current assets, FY2024, at 2024-12-31$20.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-12, accession 0001601485-26-000027.Report this figure20.9Current assets, Q1 FY2025, at 2025-03-31$20.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure22.6Current assets, Q2 FY2025, at 2025-06-30$22.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure21.5Current assets, Q3 FY2025, at 2025-09-30$21.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure19.3Current assets, FY2025, at 2025-12-31$19.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure16.2Current assets, Q1 FY2026, at 2026-03-31$16.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure25.5Current assets, Q2 FY2026, at 2026-06-30$25.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Total assets$m31.0Total assets, Q3 FY2023, at 2023-09-30$31.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-13, accession 0001601485-23-000082.Report this figure27.1Total assets, FY2023, at 2023-12-31$27.1m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-31, accession 0001601485-25-000049.Report this figure24.5Total assets, Q1 FY2024, at 2024-03-31$24.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-15, accession 0001601485-24-000033.Report this figure15.8Total assets, Q2 FY2024, at 2024-06-30$15.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001601485-24-000045.Report this figure38.4Total assets, Q3 FY2024, at 2024-09-30$38.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure28.2Total assets, FY2024, at 2024-12-31$28.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-12, accession 0001601485-26-000027.Report this figure28.1Total assets, Q1 FY2025, at 2025-03-31$28.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure29.5Total assets, Q2 FY2025, at 2025-06-30$29.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure28.3Total assets, Q3 FY2025, at 2025-09-30$28.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure25.9Total assets, FY2025, at 2025-12-31$25.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure22.7Total assets, Q1 FY2026, at 2026-03-31$22.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure31.3Total assets, Q2 FY2026, at 2026-06-30$31.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Current liabilities$m11.5Current liabilities, Q3 FY2023, at 2023-09-30$11.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-13, accession 0001601485-23-000082.Report this figure9.8Current liabilities, FY2023, at 2023-12-31$9.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-31, accession 0001601485-25-000049.Report this figure6.0Current liabilities, Q1 FY2024, at 2024-03-31$6.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-15, accession 0001601485-24-000033.Report this figure7.6Current liabilities, Q2 FY2024, at 2024-06-30$7.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001601485-24-000045.Report this figure9.0Current liabilities, Q3 FY2024, at 2024-09-30$9.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure11.5Current liabilities, FY2024, at 2024-12-31$11.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-12, accession 0001601485-26-000027.Report this figure11.4Current liabilities, Q1 FY2025, at 2025-03-31$11.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure9.9Current liabilities, Q2 FY2025, at 2025-06-30$9.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure6.5Current liabilities, Q3 FY2025, at 2025-09-30$6.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure8.1Current liabilities, FY2025, at 2025-12-31$8.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure7.2Current liabilities, Q1 FY2026, at 2026-03-31$7.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure9.2Current liabilities, Q2 FY2026, at 2026-06-30$9.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Total liabilities$m17.7Total liabilities, Q3 FY2023, at 2023-09-30$17.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-13, accession 0001601485-23-000082.Report this figure15.8Total liabilities, FY2023, at 2023-12-31$15.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-31, accession 0001601485-25-000049.Report this figure19.6Total liabilities, Q1 FY2024, at 2024-03-31$19.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-15, accession 0001601485-24-000033.Report this figure17.4Total liabilities, Q2 FY2024, at 2024-06-30$17.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001601485-24-000045.Report this figure57.4Total liabilities, Q3 FY2024, at 2024-09-30$57.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure39.5Total liabilities, FY2024, at 2024-12-31$39.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-12, accession 0001601485-26-000027.Report this figure19.2Total liabilities, Q1 FY2025, at 2025-03-31$19.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure27.7Total liabilities, Q2 FY2025, at 2025-06-30$27.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure24.5Total liabilities, Q3 FY2025, at 2025-09-30$24.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure24.2Total liabilities, FY2025, at 2025-12-31$24.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure24.1Total liabilities, Q1 FY2026, at 2026-03-31$24.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure23.4Total liabilities, Q2 FY2026, at 2026-06-30$23.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reported20.0Long-term debt, FY2024, at 2024-12-31$20.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-03-12, accession 0001601485-26-000027.Report this figurenot reported9.3Long-term debt, Q2 FY2025, at 2025-06-30$9.3m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure9.7Long-term debt, Q3 FY2025, at 2025-09-30$9.7m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure9.4Long-term debt, FY2025, at 2025-12-31$9.4m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure9.5Long-term debt, Q1 FY2026, at 2026-03-31$9.5m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure9.5Long-term debt, Q2 FY2026, at 2026-06-30$9.5m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure
Shareholders' equity$m13.3Shareholders' equity, Q3 FY2023, at 2023-09-30$13.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure11.4Shareholders' equity, FY2023, at 2023-12-31$11.4m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-12, accession 0001601485-26-000027.Report this figure4.9Shareholders' equity, Q1 FY2024, at 2024-03-31$4.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure(1.7)Shareholders' equity, Q2 FY2024, at 2024-06-30−$1.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure(19.0)Shareholders' equity, Q3 FY2024, at 2024-09-30−$19.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure(11.3)Shareholders' equity, FY2024, at 2024-12-31−$11.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure8.9Shareholders' equity, Q1 FY2025, at 2025-03-31$8.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure1.8Shareholders' equity, Q2 FY2025, at 2025-06-30$1.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure3.8Shareholders' equity, Q3 FY2025, at 2025-09-30$3.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure1.6Shareholders' equity, FY2025, at 2025-12-31$1.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure(1.4)Shareholders' equity, Q1 FY2026, at 2026-03-31−$1.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure7.9Shareholders' equity, Q2 FY2026, at 2026-06-30$7.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure

Cash flow

Operating cash flow−$8.2m, Q2 FY2026
Capital expenditure$16.0k, Q4 FY2025
Elicio Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(5.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001601485-24-000075. Derived: 9-month figure less the 6-month figure.Report this figure(9.9)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$9.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001601485-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure(12.1)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$12.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure(8.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001601485-25-000111. Derived: 6-month figure less the 3-month figure.Report this figure(7.3)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$7.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001601485-25-000124. Derived: 9-month figure less the 6-month figure.Report this figure(8.7)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$8.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure(10.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$10.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure(9.0)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$8.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001601485-26-000056. Derived: 6-month figure less the 3-month figure.Report this figure(11.1)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001601485-25-000124. Derived: 9-month figure less the 6-month figure.Report this figure(6.8)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$6.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figure(11.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$11.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure(8.2)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$8.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001601485-26-000056. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$45.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001601485-24-000075. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001601485-25-000049. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-05-15, accession 0001601485-24-000033.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$42.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0001601485-25-000111. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001601485-25-000124. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$45.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001601485-25-000124. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$16.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001601485-26-000027. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)19.24m, Q2 FY2026
Elicio Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.3Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30317,512 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-13, accession 0001601485-23-000082.Report this figure0.3Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31324,106 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-15, accession 0001601485-24-000033.Report this figure2.9Diluted shares (weighted), Q2 FY2023, three months to 2023-06-302,893,244 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001601485-24-000045.Report this figure8.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-308,376,384 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001601485-24-000075.Report this figure10.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3110,273,925 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001601485-25-000074.Report this figure11.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3011,284,853 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001601485-25-000111.Report this figure13.6Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3013,582,345 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure13.0Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3112,950,574 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure16.1Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3016,059,423 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure16.7Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3016,692,476 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001601485-25-000124.Report this figure18.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3118,211,745 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001601485-26-000042.Report this figure19.2Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3019,244,679 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure

Shares outstanding: 26.28mShares outstanding, period not labelled, at 2026-08-1126,281,882 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001601485-26-000056.Report this figure at Aug 11, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.